Only one in 12 remain on a GLP-1 drug for obesity at three years owenhaskins Jun 26, 2025 2 min read Only 8% of individuals (or one in 12) initiating a glucagon-like peptide-1 (GLP-1) agonist drug for obesity without diabetes continued to do so at three years, according to the latest real-world research from Prime Therapeutics (Prime)
Note: Please note that GLP-1 RAs are prescription medications and must be used only under the supervision of a qualified healthcare professional
GonzlezEnseat International Journal of Dermatology 58(12):p 1466-1467, December 2019
And GLP-1s were recently approved to treat MASH, an inflammatory form of fatty liver disease, and are being studied for the cognitive benefits in Parkinsons patients
The lid is made from safe, food-grade SAN plastic, ensuring durability and protection without harmful materials
High ATP amounts induce the closure of potassium channels, depolarizing the cell membrane, leading to calcium influx and insulin vesicle release